Rare

Investors are currently facing concerns over inflation and the uncertainty surrounding Federal Reserve rate cuts, resulting in turbulent markets. However, amidst this volatility, long-term investors can benefit from the stock research provided by Wall Street analysts. One of the top picks by analysts is workplace management software maker Monday.com (MNDY). The company recently reported impressive
0 Comments
The Food and Drug Administration’s recent announcement approving Pfizer’s treatment for hemophilia B marks a significant milestone in the field of gene therapy. The drug, known as Beqvez, is the first gene therapy from Pfizer to receive clearance in the U.S., offering new hope for adults with moderate to severe hemophilia B. Beqvez is a
0 Comments
Walgreens recently announced its plans to partner directly with drugmakers to provide cell and gene therapies to patients in the United States. This initiative is part of a broader expansion of the company’s specialty pharmacy services. The establishment of a new business unit dedicated to the specialty pharmacy segment, which includes AllianceRx as a subsidiary,
0 Comments